Monitoring anti-Xa levels in patients with cancer-associated venous thromboembolism treated with bemiparin
Objective To analyze the relationship between therapeutic (weight-adjusted) dose of bemiparin and anti-Xa activity in patients with venous thromboembolism (VTE) and cancer in comparison with a cohort of patients with VTE without cancer, and its relationship with outcomes. Materials and methods This...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Galeano-Valle, F. [verfasserIn] Pérez-Rus, G. [verfasserIn] Demelo-Rodríguez, P. [verfasserIn] Ordieres-Ortega, L. [verfasserIn] Ortega-Morán, L. [verfasserIn] Muñoz-Martín, A. J. [verfasserIn] Medina-Molina, S. [verfasserIn] Alvarez-Sala-Walther, L. A. [verfasserIn] del-Toro-Cervera, J. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2019 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: Revista de oncología - Barcelona : Doyma, 2000, 22(2019), 8 vom: 20. Dez., Seite 1312-1320 |
|---|---|
| Übergeordnetes Werk: |
volume:22 ; year:2019 ; number:8 ; day:20 ; month:12 ; pages:1312-1320 |
| Links: |
|---|
| DOI / URN: |
10.1007/s12094-019-02258-w |
|---|
| Katalog-ID: |
SPR040149463 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR040149463 | ||
| 003 | DE-627 | ||
| 005 | 20230519113041.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12094-019-02258-w |2 doi | |
| 035 | |a (DE-627)SPR040149463 | ||
| 035 | |a (SPR)s12094-019-02258-w-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 100 | 1 | |a Galeano-Valle, F. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Monitoring anti-Xa levels in patients with cancer-associated venous thromboembolism treated with bemiparin |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Objective To analyze the relationship between therapeutic (weight-adjusted) dose of bemiparin and anti-Xa activity in patients with venous thromboembolism (VTE) and cancer in comparison with a cohort of patients with VTE without cancer, and its relationship with outcomes. Materials and methods This is a prospective cohort study that comprised a cohort of patients with cancer-associated VTE and a cohort of non-cancer patients with VTE, all of them treated with bemiparin. The ethics committee approved the study and informed consent was obtained from the patients. Results One hundred patients were included (52 with cancer and 48 without cancer), with a median follow-up of 9.8 months. Mean anti-Xa activity was 0.89 (± 0.33) UI/mL in oncological patients and 0.83 (± 0.30) UI/mL in non-cancer patients (mean difference − 0.05 95% CI − 0.18; 0.06). A multiple linear regression model showed that anti-Xa peak was associated with the dose/kg independently of possible confounding variables (presence of cancer, age, sex and eGFR—estimated Glomerular Filtration Rate), in a way that for every 1 UI of dose/kg increase, the anti-Xa peak activity increased 0.006 UI/mL (95% CI 0.003; 0.009) (p < 0.001). The predictive capacity of anti-Xa peak in the oncology cohort showed an area under the ROC curve of 0.46 (95% CI 0.24–0.68), 0.70 (95% CI 0.49–0.91) and 0.74 (95% CI 0.44–0.94) for death, first bleeding and recurrence of VTE, respectively, and none was statistically significant. Conclusion In patients with venous thromboembolism treated with bemiparin, anti-Xa levels were not influenced by the presence of cancer. | ||
| 650 | 4 | |a Anti-Xa |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Anticoagulation |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Bemiparin |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Cancer |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Venous thromboembolism |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Pérez-Rus, G. |e verfasserin |4 aut | |
| 700 | 1 | |a Demelo-Rodríguez, P. |e verfasserin |4 aut | |
| 700 | 1 | |a Ordieres-Ortega, L. |e verfasserin |4 aut | |
| 700 | 1 | |a Ortega-Morán, L. |e verfasserin |4 aut | |
| 700 | 1 | |a Muñoz-Martín, A. J. |e verfasserin |4 aut | |
| 700 | 1 | |a Medina-Molina, S. |e verfasserin |4 aut | |
| 700 | 1 | |a Alvarez-Sala-Walther, L. A. |e verfasserin |4 aut | |
| 700 | 1 | |a del-Toro-Cervera, J. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revista de oncología |d Barcelona : Doyma, 2000 |g 22(2019), 8 vom: 20. Dez., Seite 1312-1320 |w (DE-627)385985452 |w (DE-600)2143451-7 |x 1578-195X |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2019 |g number:8 |g day:20 |g month:12 |g pages:1312-1320 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s12094-019-02258-w |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_31 | ||
| 912 | |a GBV_ILN_39 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_70 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_90 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_100 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_120 | ||
| 912 | |a GBV_ILN_152 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_171 | ||
| 912 | |a GBV_ILN_187 | ||
| 912 | |a GBV_ILN_224 | ||
| 912 | |a GBV_ILN_250 | ||
| 912 | |a GBV_ILN_281 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_370 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_702 | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2019 |e 8 |b 20 |c 12 |h 1312-1320 | ||
| author_variant |
f g v fgv g p r gpr p d r pdr l o o loo l o m lom a j m m ajm ajmm s m m smm l a a s laa laas j d t jdt |
|---|---|
| matchkey_str |
article:1578195X:2019----::oioigniaeesnainsihacrsoitdeoshobeb |
| hierarchy_sort_str |
2019 |
| publishDate |
2019 |
| allfields |
10.1007/s12094-019-02258-w doi (DE-627)SPR040149463 (SPR)s12094-019-02258-w-e DE-627 ger DE-627 rakwb eng 610 ASE Galeano-Valle, F. verfasserin aut Monitoring anti-Xa levels in patients with cancer-associated venous thromboembolism treated with bemiparin 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objective To analyze the relationship between therapeutic (weight-adjusted) dose of bemiparin and anti-Xa activity in patients with venous thromboembolism (VTE) and cancer in comparison with a cohort of patients with VTE without cancer, and its relationship with outcomes. Materials and methods This is a prospective cohort study that comprised a cohort of patients with cancer-associated VTE and a cohort of non-cancer patients with VTE, all of them treated with bemiparin. The ethics committee approved the study and informed consent was obtained from the patients. Results One hundred patients were included (52 with cancer and 48 without cancer), with a median follow-up of 9.8 months. Mean anti-Xa activity was 0.89 (± 0.33) UI/mL in oncological patients and 0.83 (± 0.30) UI/mL in non-cancer patients (mean difference − 0.05 95% CI − 0.18; 0.06). A multiple linear regression model showed that anti-Xa peak was associated with the dose/kg independently of possible confounding variables (presence of cancer, age, sex and eGFR—estimated Glomerular Filtration Rate), in a way that for every 1 UI of dose/kg increase, the anti-Xa peak activity increased 0.006 UI/mL (95% CI 0.003; 0.009) (p < 0.001). The predictive capacity of anti-Xa peak in the oncology cohort showed an area under the ROC curve of 0.46 (95% CI 0.24–0.68), 0.70 (95% CI 0.49–0.91) and 0.74 (95% CI 0.44–0.94) for death, first bleeding and recurrence of VTE, respectively, and none was statistically significant. Conclusion In patients with venous thromboembolism treated with bemiparin, anti-Xa levels were not influenced by the presence of cancer. Anti-Xa (dpeaa)DE-He213 Anticoagulation (dpeaa)DE-He213 Bemiparin (dpeaa)DE-He213 Cancer (dpeaa)DE-He213 Venous thromboembolism (dpeaa)DE-He213 Pérez-Rus, G. verfasserin aut Demelo-Rodríguez, P. verfasserin aut Ordieres-Ortega, L. verfasserin aut Ortega-Morán, L. verfasserin aut Muñoz-Martín, A. J. verfasserin aut Medina-Molina, S. verfasserin aut Alvarez-Sala-Walther, L. A. verfasserin aut del-Toro-Cervera, J. verfasserin aut Enthalten in Revista de oncología Barcelona : Doyma, 2000 22(2019), 8 vom: 20. Dez., Seite 1312-1320 (DE-627)385985452 (DE-600)2143451-7 1578-195X nnns volume:22 year:2019 number:8 day:20 month:12 pages:1312-1320 https://dx.doi.org/10.1007/s12094-019-02258-w lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 22 2019 8 20 12 1312-1320 |
| spelling |
10.1007/s12094-019-02258-w doi (DE-627)SPR040149463 (SPR)s12094-019-02258-w-e DE-627 ger DE-627 rakwb eng 610 ASE Galeano-Valle, F. verfasserin aut Monitoring anti-Xa levels in patients with cancer-associated venous thromboembolism treated with bemiparin 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objective To analyze the relationship between therapeutic (weight-adjusted) dose of bemiparin and anti-Xa activity in patients with venous thromboembolism (VTE) and cancer in comparison with a cohort of patients with VTE without cancer, and its relationship with outcomes. Materials and methods This is a prospective cohort study that comprised a cohort of patients with cancer-associated VTE and a cohort of non-cancer patients with VTE, all of them treated with bemiparin. The ethics committee approved the study and informed consent was obtained from the patients. Results One hundred patients were included (52 with cancer and 48 without cancer), with a median follow-up of 9.8 months. Mean anti-Xa activity was 0.89 (± 0.33) UI/mL in oncological patients and 0.83 (± 0.30) UI/mL in non-cancer patients (mean difference − 0.05 95% CI − 0.18; 0.06). A multiple linear regression model showed that anti-Xa peak was associated with the dose/kg independently of possible confounding variables (presence of cancer, age, sex and eGFR—estimated Glomerular Filtration Rate), in a way that for every 1 UI of dose/kg increase, the anti-Xa peak activity increased 0.006 UI/mL (95% CI 0.003; 0.009) (p < 0.001). The predictive capacity of anti-Xa peak in the oncology cohort showed an area under the ROC curve of 0.46 (95% CI 0.24–0.68), 0.70 (95% CI 0.49–0.91) and 0.74 (95% CI 0.44–0.94) for death, first bleeding and recurrence of VTE, respectively, and none was statistically significant. Conclusion In patients with venous thromboembolism treated with bemiparin, anti-Xa levels were not influenced by the presence of cancer. Anti-Xa (dpeaa)DE-He213 Anticoagulation (dpeaa)DE-He213 Bemiparin (dpeaa)DE-He213 Cancer (dpeaa)DE-He213 Venous thromboembolism (dpeaa)DE-He213 Pérez-Rus, G. verfasserin aut Demelo-Rodríguez, P. verfasserin aut Ordieres-Ortega, L. verfasserin aut Ortega-Morán, L. verfasserin aut Muñoz-Martín, A. J. verfasserin aut Medina-Molina, S. verfasserin aut Alvarez-Sala-Walther, L. A. verfasserin aut del-Toro-Cervera, J. verfasserin aut Enthalten in Revista de oncología Barcelona : Doyma, 2000 22(2019), 8 vom: 20. Dez., Seite 1312-1320 (DE-627)385985452 (DE-600)2143451-7 1578-195X nnns volume:22 year:2019 number:8 day:20 month:12 pages:1312-1320 https://dx.doi.org/10.1007/s12094-019-02258-w lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 22 2019 8 20 12 1312-1320 |
| allfields_unstemmed |
10.1007/s12094-019-02258-w doi (DE-627)SPR040149463 (SPR)s12094-019-02258-w-e DE-627 ger DE-627 rakwb eng 610 ASE Galeano-Valle, F. verfasserin aut Monitoring anti-Xa levels in patients with cancer-associated venous thromboembolism treated with bemiparin 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objective To analyze the relationship between therapeutic (weight-adjusted) dose of bemiparin and anti-Xa activity in patients with venous thromboembolism (VTE) and cancer in comparison with a cohort of patients with VTE without cancer, and its relationship with outcomes. Materials and methods This is a prospective cohort study that comprised a cohort of patients with cancer-associated VTE and a cohort of non-cancer patients with VTE, all of them treated with bemiparin. The ethics committee approved the study and informed consent was obtained from the patients. Results One hundred patients were included (52 with cancer and 48 without cancer), with a median follow-up of 9.8 months. Mean anti-Xa activity was 0.89 (± 0.33) UI/mL in oncological patients and 0.83 (± 0.30) UI/mL in non-cancer patients (mean difference − 0.05 95% CI − 0.18; 0.06). A multiple linear regression model showed that anti-Xa peak was associated with the dose/kg independently of possible confounding variables (presence of cancer, age, sex and eGFR—estimated Glomerular Filtration Rate), in a way that for every 1 UI of dose/kg increase, the anti-Xa peak activity increased 0.006 UI/mL (95% CI 0.003; 0.009) (p < 0.001). The predictive capacity of anti-Xa peak in the oncology cohort showed an area under the ROC curve of 0.46 (95% CI 0.24–0.68), 0.70 (95% CI 0.49–0.91) and 0.74 (95% CI 0.44–0.94) for death, first bleeding and recurrence of VTE, respectively, and none was statistically significant. Conclusion In patients with venous thromboembolism treated with bemiparin, anti-Xa levels were not influenced by the presence of cancer. Anti-Xa (dpeaa)DE-He213 Anticoagulation (dpeaa)DE-He213 Bemiparin (dpeaa)DE-He213 Cancer (dpeaa)DE-He213 Venous thromboembolism (dpeaa)DE-He213 Pérez-Rus, G. verfasserin aut Demelo-Rodríguez, P. verfasserin aut Ordieres-Ortega, L. verfasserin aut Ortega-Morán, L. verfasserin aut Muñoz-Martín, A. J. verfasserin aut Medina-Molina, S. verfasserin aut Alvarez-Sala-Walther, L. A. verfasserin aut del-Toro-Cervera, J. verfasserin aut Enthalten in Revista de oncología Barcelona : Doyma, 2000 22(2019), 8 vom: 20. Dez., Seite 1312-1320 (DE-627)385985452 (DE-600)2143451-7 1578-195X nnns volume:22 year:2019 number:8 day:20 month:12 pages:1312-1320 https://dx.doi.org/10.1007/s12094-019-02258-w lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 22 2019 8 20 12 1312-1320 |
| allfieldsGer |
10.1007/s12094-019-02258-w doi (DE-627)SPR040149463 (SPR)s12094-019-02258-w-e DE-627 ger DE-627 rakwb eng 610 ASE Galeano-Valle, F. verfasserin aut Monitoring anti-Xa levels in patients with cancer-associated venous thromboembolism treated with bemiparin 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objective To analyze the relationship between therapeutic (weight-adjusted) dose of bemiparin and anti-Xa activity in patients with venous thromboembolism (VTE) and cancer in comparison with a cohort of patients with VTE without cancer, and its relationship with outcomes. Materials and methods This is a prospective cohort study that comprised a cohort of patients with cancer-associated VTE and a cohort of non-cancer patients with VTE, all of them treated with bemiparin. The ethics committee approved the study and informed consent was obtained from the patients. Results One hundred patients were included (52 with cancer and 48 without cancer), with a median follow-up of 9.8 months. Mean anti-Xa activity was 0.89 (± 0.33) UI/mL in oncological patients and 0.83 (± 0.30) UI/mL in non-cancer patients (mean difference − 0.05 95% CI − 0.18; 0.06). A multiple linear regression model showed that anti-Xa peak was associated with the dose/kg independently of possible confounding variables (presence of cancer, age, sex and eGFR—estimated Glomerular Filtration Rate), in a way that for every 1 UI of dose/kg increase, the anti-Xa peak activity increased 0.006 UI/mL (95% CI 0.003; 0.009) (p < 0.001). The predictive capacity of anti-Xa peak in the oncology cohort showed an area under the ROC curve of 0.46 (95% CI 0.24–0.68), 0.70 (95% CI 0.49–0.91) and 0.74 (95% CI 0.44–0.94) for death, first bleeding and recurrence of VTE, respectively, and none was statistically significant. Conclusion In patients with venous thromboembolism treated with bemiparin, anti-Xa levels were not influenced by the presence of cancer. Anti-Xa (dpeaa)DE-He213 Anticoagulation (dpeaa)DE-He213 Bemiparin (dpeaa)DE-He213 Cancer (dpeaa)DE-He213 Venous thromboembolism (dpeaa)DE-He213 Pérez-Rus, G. verfasserin aut Demelo-Rodríguez, P. verfasserin aut Ordieres-Ortega, L. verfasserin aut Ortega-Morán, L. verfasserin aut Muñoz-Martín, A. J. verfasserin aut Medina-Molina, S. verfasserin aut Alvarez-Sala-Walther, L. A. verfasserin aut del-Toro-Cervera, J. verfasserin aut Enthalten in Revista de oncología Barcelona : Doyma, 2000 22(2019), 8 vom: 20. Dez., Seite 1312-1320 (DE-627)385985452 (DE-600)2143451-7 1578-195X nnns volume:22 year:2019 number:8 day:20 month:12 pages:1312-1320 https://dx.doi.org/10.1007/s12094-019-02258-w lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 22 2019 8 20 12 1312-1320 |
| allfieldsSound |
10.1007/s12094-019-02258-w doi (DE-627)SPR040149463 (SPR)s12094-019-02258-w-e DE-627 ger DE-627 rakwb eng 610 ASE Galeano-Valle, F. verfasserin aut Monitoring anti-Xa levels in patients with cancer-associated venous thromboembolism treated with bemiparin 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objective To analyze the relationship between therapeutic (weight-adjusted) dose of bemiparin and anti-Xa activity in patients with venous thromboembolism (VTE) and cancer in comparison with a cohort of patients with VTE without cancer, and its relationship with outcomes. Materials and methods This is a prospective cohort study that comprised a cohort of patients with cancer-associated VTE and a cohort of non-cancer patients with VTE, all of them treated with bemiparin. The ethics committee approved the study and informed consent was obtained from the patients. Results One hundred patients were included (52 with cancer and 48 without cancer), with a median follow-up of 9.8 months. Mean anti-Xa activity was 0.89 (± 0.33) UI/mL in oncological patients and 0.83 (± 0.30) UI/mL in non-cancer patients (mean difference − 0.05 95% CI − 0.18; 0.06). A multiple linear regression model showed that anti-Xa peak was associated with the dose/kg independently of possible confounding variables (presence of cancer, age, sex and eGFR—estimated Glomerular Filtration Rate), in a way that for every 1 UI of dose/kg increase, the anti-Xa peak activity increased 0.006 UI/mL (95% CI 0.003; 0.009) (p < 0.001). The predictive capacity of anti-Xa peak in the oncology cohort showed an area under the ROC curve of 0.46 (95% CI 0.24–0.68), 0.70 (95% CI 0.49–0.91) and 0.74 (95% CI 0.44–0.94) for death, first bleeding and recurrence of VTE, respectively, and none was statistically significant. Conclusion In patients with venous thromboembolism treated with bemiparin, anti-Xa levels were not influenced by the presence of cancer. Anti-Xa (dpeaa)DE-He213 Anticoagulation (dpeaa)DE-He213 Bemiparin (dpeaa)DE-He213 Cancer (dpeaa)DE-He213 Venous thromboembolism (dpeaa)DE-He213 Pérez-Rus, G. verfasserin aut Demelo-Rodríguez, P. verfasserin aut Ordieres-Ortega, L. verfasserin aut Ortega-Morán, L. verfasserin aut Muñoz-Martín, A. J. verfasserin aut Medina-Molina, S. verfasserin aut Alvarez-Sala-Walther, L. A. verfasserin aut del-Toro-Cervera, J. verfasserin aut Enthalten in Revista de oncología Barcelona : Doyma, 2000 22(2019), 8 vom: 20. Dez., Seite 1312-1320 (DE-627)385985452 (DE-600)2143451-7 1578-195X nnns volume:22 year:2019 number:8 day:20 month:12 pages:1312-1320 https://dx.doi.org/10.1007/s12094-019-02258-w lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 22 2019 8 20 12 1312-1320 |
| language |
English |
| source |
Enthalten in Revista de oncología 22(2019), 8 vom: 20. Dez., Seite 1312-1320 volume:22 year:2019 number:8 day:20 month:12 pages:1312-1320 |
| sourceStr |
Enthalten in Revista de oncología 22(2019), 8 vom: 20. Dez., Seite 1312-1320 volume:22 year:2019 number:8 day:20 month:12 pages:1312-1320 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Anti-Xa Anticoagulation Bemiparin Cancer Venous thromboembolism |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Revista de oncología |
| authorswithroles_txt_mv |
Galeano-Valle, F. @@aut@@ Pérez-Rus, G. @@aut@@ Demelo-Rodríguez, P. @@aut@@ Ordieres-Ortega, L. @@aut@@ Ortega-Morán, L. @@aut@@ Muñoz-Martín, A. J. @@aut@@ Medina-Molina, S. @@aut@@ Alvarez-Sala-Walther, L. A. @@aut@@ del-Toro-Cervera, J. @@aut@@ |
| publishDateDaySort_date |
2019-12-20T00:00:00Z |
| hierarchy_top_id |
385985452 |
| dewey-sort |
3610 |
| id |
SPR040149463 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR040149463</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519113041.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s12094-019-02258-w</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR040149463</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s12094-019-02258-w-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Galeano-Valle, F.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Monitoring anti-Xa levels in patients with cancer-associated venous thromboembolism treated with bemiparin</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Objective To analyze the relationship between therapeutic (weight-adjusted) dose of bemiparin and anti-Xa activity in patients with venous thromboembolism (VTE) and cancer in comparison with a cohort of patients with VTE without cancer, and its relationship with outcomes. Materials and methods This is a prospective cohort study that comprised a cohort of patients with cancer-associated VTE and a cohort of non-cancer patients with VTE, all of them treated with bemiparin. The ethics committee approved the study and informed consent was obtained from the patients. Results One hundred patients were included (52 with cancer and 48 without cancer), with a median follow-up of 9.8 months. Mean anti-Xa activity was 0.89 (± 0.33) UI/mL in oncological patients and 0.83 (± 0.30) UI/mL in non-cancer patients (mean difference − 0.05 95% CI − 0.18; 0.06). A multiple linear regression model showed that anti-Xa peak was associated with the dose/kg independently of possible confounding variables (presence of cancer, age, sex and eGFR—estimated Glomerular Filtration Rate), in a way that for every 1 UI of dose/kg increase, the anti-Xa peak activity increased 0.006 UI/mL (95% CI 0.003; 0.009) (p < 0.001). The predictive capacity of anti-Xa peak in the oncology cohort showed an area under the ROC curve of 0.46 (95% CI 0.24–0.68), 0.70 (95% CI 0.49–0.91) and 0.74 (95% CI 0.44–0.94) for death, first bleeding and recurrence of VTE, respectively, and none was statistically significant. Conclusion In patients with venous thromboembolism treated with bemiparin, anti-Xa levels were not influenced by the presence of cancer.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Anti-Xa</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Anticoagulation</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Bemiparin</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Venous thromboembolism</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pérez-Rus, G.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Demelo-Rodríguez, P.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ordieres-Ortega, L.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ortega-Morán, L.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Muñoz-Martín, A. J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Medina-Molina, S.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Alvarez-Sala-Walther, L. A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">del-Toro-Cervera, J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Revista de oncología</subfield><subfield code="d">Barcelona : Doyma, 2000</subfield><subfield code="g">22(2019), 8 vom: 20. Dez., Seite 1312-1320</subfield><subfield code="w">(DE-627)385985452</subfield><subfield code="w">(DE-600)2143451-7</subfield><subfield code="x">1578-195X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:22</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:8</subfield><subfield code="g">day:20</subfield><subfield code="g">month:12</subfield><subfield code="g">pages:1312-1320</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s12094-019-02258-w</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">22</subfield><subfield code="j">2019</subfield><subfield code="e">8</subfield><subfield code="b">20</subfield><subfield code="c">12</subfield><subfield code="h">1312-1320</subfield></datafield></record></collection>
|
| author |
Galeano-Valle, F. |
| spellingShingle |
Galeano-Valle, F. ddc 610 misc Anti-Xa misc Anticoagulation misc Bemiparin misc Cancer misc Venous thromboembolism Monitoring anti-Xa levels in patients with cancer-associated venous thromboembolism treated with bemiparin |
| authorStr |
Galeano-Valle, F. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)385985452 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1578-195X |
| topic_title |
610 ASE Monitoring anti-Xa levels in patients with cancer-associated venous thromboembolism treated with bemiparin Anti-Xa (dpeaa)DE-He213 Anticoagulation (dpeaa)DE-He213 Bemiparin (dpeaa)DE-He213 Cancer (dpeaa)DE-He213 Venous thromboembolism (dpeaa)DE-He213 |
| topic |
ddc 610 misc Anti-Xa misc Anticoagulation misc Bemiparin misc Cancer misc Venous thromboembolism |
| topic_unstemmed |
ddc 610 misc Anti-Xa misc Anticoagulation misc Bemiparin misc Cancer misc Venous thromboembolism |
| topic_browse |
ddc 610 misc Anti-Xa misc Anticoagulation misc Bemiparin misc Cancer misc Venous thromboembolism |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Revista de oncología |
| hierarchy_parent_id |
385985452 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Revista de oncología |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)385985452 (DE-600)2143451-7 |
| title |
Monitoring anti-Xa levels in patients with cancer-associated venous thromboembolism treated with bemiparin |
| ctrlnum |
(DE-627)SPR040149463 (SPR)s12094-019-02258-w-e |
| title_full |
Monitoring anti-Xa levels in patients with cancer-associated venous thromboembolism treated with bemiparin |
| author_sort |
Galeano-Valle, F. |
| journal |
Revista de oncología |
| journalStr |
Revista de oncología |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2019 |
| contenttype_str_mv |
txt |
| container_start_page |
1312 |
| author_browse |
Galeano-Valle, F. Pérez-Rus, G. Demelo-Rodríguez, P. Ordieres-Ortega, L. Ortega-Morán, L. Muñoz-Martín, A. J. Medina-Molina, S. Alvarez-Sala-Walther, L. A. del-Toro-Cervera, J. |
| container_volume |
22 |
| class |
610 ASE |
| format_se |
Elektronische Aufsätze |
| author-letter |
Galeano-Valle, F. |
| doi_str_mv |
10.1007/s12094-019-02258-w |
| dewey-full |
610 |
| author2-role |
verfasserin |
| title_sort |
monitoring anti-xa levels in patients with cancer-associated venous thromboembolism treated with bemiparin |
| title_auth |
Monitoring anti-Xa levels in patients with cancer-associated venous thromboembolism treated with bemiparin |
| abstract |
Objective To analyze the relationship between therapeutic (weight-adjusted) dose of bemiparin and anti-Xa activity in patients with venous thromboembolism (VTE) and cancer in comparison with a cohort of patients with VTE without cancer, and its relationship with outcomes. Materials and methods This is a prospective cohort study that comprised a cohort of patients with cancer-associated VTE and a cohort of non-cancer patients with VTE, all of them treated with bemiparin. The ethics committee approved the study and informed consent was obtained from the patients. Results One hundred patients were included (52 with cancer and 48 without cancer), with a median follow-up of 9.8 months. Mean anti-Xa activity was 0.89 (± 0.33) UI/mL in oncological patients and 0.83 (± 0.30) UI/mL in non-cancer patients (mean difference − 0.05 95% CI − 0.18; 0.06). A multiple linear regression model showed that anti-Xa peak was associated with the dose/kg independently of possible confounding variables (presence of cancer, age, sex and eGFR—estimated Glomerular Filtration Rate), in a way that for every 1 UI of dose/kg increase, the anti-Xa peak activity increased 0.006 UI/mL (95% CI 0.003; 0.009) (p < 0.001). The predictive capacity of anti-Xa peak in the oncology cohort showed an area under the ROC curve of 0.46 (95% CI 0.24–0.68), 0.70 (95% CI 0.49–0.91) and 0.74 (95% CI 0.44–0.94) for death, first bleeding and recurrence of VTE, respectively, and none was statistically significant. Conclusion In patients with venous thromboembolism treated with bemiparin, anti-Xa levels were not influenced by the presence of cancer. |
| abstractGer |
Objective To analyze the relationship between therapeutic (weight-adjusted) dose of bemiparin and anti-Xa activity in patients with venous thromboembolism (VTE) and cancer in comparison with a cohort of patients with VTE without cancer, and its relationship with outcomes. Materials and methods This is a prospective cohort study that comprised a cohort of patients with cancer-associated VTE and a cohort of non-cancer patients with VTE, all of them treated with bemiparin. The ethics committee approved the study and informed consent was obtained from the patients. Results One hundred patients were included (52 with cancer and 48 without cancer), with a median follow-up of 9.8 months. Mean anti-Xa activity was 0.89 (± 0.33) UI/mL in oncological patients and 0.83 (± 0.30) UI/mL in non-cancer patients (mean difference − 0.05 95% CI − 0.18; 0.06). A multiple linear regression model showed that anti-Xa peak was associated with the dose/kg independently of possible confounding variables (presence of cancer, age, sex and eGFR—estimated Glomerular Filtration Rate), in a way that for every 1 UI of dose/kg increase, the anti-Xa peak activity increased 0.006 UI/mL (95% CI 0.003; 0.009) (p < 0.001). The predictive capacity of anti-Xa peak in the oncology cohort showed an area under the ROC curve of 0.46 (95% CI 0.24–0.68), 0.70 (95% CI 0.49–0.91) and 0.74 (95% CI 0.44–0.94) for death, first bleeding and recurrence of VTE, respectively, and none was statistically significant. Conclusion In patients with venous thromboembolism treated with bemiparin, anti-Xa levels were not influenced by the presence of cancer. |
| abstract_unstemmed |
Objective To analyze the relationship between therapeutic (weight-adjusted) dose of bemiparin and anti-Xa activity in patients with venous thromboembolism (VTE) and cancer in comparison with a cohort of patients with VTE without cancer, and its relationship with outcomes. Materials and methods This is a prospective cohort study that comprised a cohort of patients with cancer-associated VTE and a cohort of non-cancer patients with VTE, all of them treated with bemiparin. The ethics committee approved the study and informed consent was obtained from the patients. Results One hundred patients were included (52 with cancer and 48 without cancer), with a median follow-up of 9.8 months. Mean anti-Xa activity was 0.89 (± 0.33) UI/mL in oncological patients and 0.83 (± 0.30) UI/mL in non-cancer patients (mean difference − 0.05 95% CI − 0.18; 0.06). A multiple linear regression model showed that anti-Xa peak was associated with the dose/kg independently of possible confounding variables (presence of cancer, age, sex and eGFR—estimated Glomerular Filtration Rate), in a way that for every 1 UI of dose/kg increase, the anti-Xa peak activity increased 0.006 UI/mL (95% CI 0.003; 0.009) (p < 0.001). The predictive capacity of anti-Xa peak in the oncology cohort showed an area under the ROC curve of 0.46 (95% CI 0.24–0.68), 0.70 (95% CI 0.49–0.91) and 0.74 (95% CI 0.44–0.94) for death, first bleeding and recurrence of VTE, respectively, and none was statistically significant. Conclusion In patients with venous thromboembolism treated with bemiparin, anti-Xa levels were not influenced by the presence of cancer. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 |
| container_issue |
8 |
| title_short |
Monitoring anti-Xa levels in patients with cancer-associated venous thromboembolism treated with bemiparin |
| url |
https://dx.doi.org/10.1007/s12094-019-02258-w |
| remote_bool |
true |
| author2 |
Pérez-Rus, G. Demelo-Rodríguez, P. Ordieres-Ortega, L. Ortega-Morán, L. Muñoz-Martín, A. J. Medina-Molina, S. Alvarez-Sala-Walther, L. A. del-Toro-Cervera, J. |
| author2Str |
Pérez-Rus, G. Demelo-Rodríguez, P. Ordieres-Ortega, L. Ortega-Morán, L. Muñoz-Martín, A. J. Medina-Molina, S. Alvarez-Sala-Walther, L. A. del-Toro-Cervera, J. |
| ppnlink |
385985452 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/s12094-019-02258-w |
| up_date |
2024-07-03T14:06:34.157Z |
| _version_ |
1803567071671353344 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR040149463</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519113041.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s12094-019-02258-w</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR040149463</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s12094-019-02258-w-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Galeano-Valle, F.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Monitoring anti-Xa levels in patients with cancer-associated venous thromboembolism treated with bemiparin</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Objective To analyze the relationship between therapeutic (weight-adjusted) dose of bemiparin and anti-Xa activity in patients with venous thromboembolism (VTE) and cancer in comparison with a cohort of patients with VTE without cancer, and its relationship with outcomes. Materials and methods This is a prospective cohort study that comprised a cohort of patients with cancer-associated VTE and a cohort of non-cancer patients with VTE, all of them treated with bemiparin. The ethics committee approved the study and informed consent was obtained from the patients. Results One hundred patients were included (52 with cancer and 48 without cancer), with a median follow-up of 9.8 months. Mean anti-Xa activity was 0.89 (± 0.33) UI/mL in oncological patients and 0.83 (± 0.30) UI/mL in non-cancer patients (mean difference − 0.05 95% CI − 0.18; 0.06). A multiple linear regression model showed that anti-Xa peak was associated with the dose/kg independently of possible confounding variables (presence of cancer, age, sex and eGFR—estimated Glomerular Filtration Rate), in a way that for every 1 UI of dose/kg increase, the anti-Xa peak activity increased 0.006 UI/mL (95% CI 0.003; 0.009) (p < 0.001). The predictive capacity of anti-Xa peak in the oncology cohort showed an area under the ROC curve of 0.46 (95% CI 0.24–0.68), 0.70 (95% CI 0.49–0.91) and 0.74 (95% CI 0.44–0.94) for death, first bleeding and recurrence of VTE, respectively, and none was statistically significant. Conclusion In patients with venous thromboembolism treated with bemiparin, anti-Xa levels were not influenced by the presence of cancer.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Anti-Xa</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Anticoagulation</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Bemiparin</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Venous thromboembolism</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pérez-Rus, G.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Demelo-Rodríguez, P.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ordieres-Ortega, L.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ortega-Morán, L.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Muñoz-Martín, A. J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Medina-Molina, S.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Alvarez-Sala-Walther, L. A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">del-Toro-Cervera, J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Revista de oncología</subfield><subfield code="d">Barcelona : Doyma, 2000</subfield><subfield code="g">22(2019), 8 vom: 20. Dez., Seite 1312-1320</subfield><subfield code="w">(DE-627)385985452</subfield><subfield code="w">(DE-600)2143451-7</subfield><subfield code="x">1578-195X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:22</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:8</subfield><subfield code="g">day:20</subfield><subfield code="g">month:12</subfield><subfield code="g">pages:1312-1320</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s12094-019-02258-w</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">22</subfield><subfield code="j">2019</subfield><subfield code="e">8</subfield><subfield code="b">20</subfield><subfield code="c">12</subfield><subfield code="h">1312-1320</subfield></datafield></record></collection>
|
| score |
7.3987446 |